Centogene and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine today announced a strategic research collaboration to improve health outcomes for rare disease patients by accelerating and de-risking drug discovery and clinical development. As part of the collaboration, CENTOGENE and the Lab will leverage the CENTOGENE Biodatabank, which contains over 70 million unique genetic variants collected from more than 800,000 patients from over 120 countries – providing valuable and unparalleled insights into the role that specific genes play in disease. Together, CENTOGENE and the Lab will jointly agree on future research projects that will integrate multiomics and bioinformatics to analyze this highly diverse data to discover and validate novel genetic and biochemical targets that can be used for future development of rare disease therapies. By proving and validating the relevance of a target to disease and that modulating it will have the desired outcome, drug discovery and development can be significantly accelerated and de-risked. Specific targets of the collaboration have not been disclosed.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CNTG:
- CENTOGENE and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine Announce Rare Disease Research Collaboration
- CENTOGENE Receives French Research Tax Credit Accreditation
- CENTOGENE and The Michael J. Fox Foundation Announce Research Project to Validate Genetic Risk Factors of Parkinson’s Disease Using Multiomics
- CENTOGENE Announces Preliminary Full Year 2023 Revenue
- CENTOGENE Announces Voting Results of Extraordinary General Meeting